Category Archives: OTC

Starpharma Holdings Ltd. (SPHRY: OTCQX International) | VivaGel Active against Zika Virus

VivaGel Active against Zika Virus

May 05, 2016

OTC Disclosure News Service

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that
the VivaGel® active, astodrimer sodium (SPL7013), has been
shown to have potent antiviral activity against the Zika virus in
laboratory studies. The studies showed near complete antiviral
protection at SPL7013 concentrations significantly below that used in
the VivaGel® condom.

In February 2016, the World Health Organization (WHO) declared the Zika
virus outbreak a global emergency. It now affects more than 40 countries
in total – 20 countries in the Americas, most of the Caribbean and
several in the Pacific. The most significant outbreak, and resulting
effects on babies, has been reported in Brazil, where an estimated one
million people have already been infected with Zika.

Although Zika is a mosquito-borne virus, it is now also confirmed to be
a sexually transmitted infection (STI). The US Centers for Disease
Control and Prevention (CDC) has reported more than 425
travel-associated cases of Zika virus and there are now a growing number
of people infected through sexual transmission by travelers returning
from affected areas. Many cases of sexual transmission of Zika virus
have now been reported in other countries.

Zika virus infection is of particular concern during pregnancy. The CDC
recently confirmed that there is now enough evidence to conclude that
Zika virus infection during pregnancy is a cause of microcephaly and
other severe foetal brain defects, and has been linked to problems in
infants, including eye defects, hearing loss and impaired growth.

Due to the implications for effects during pregnancy, particularly
concerning are cases where Zika virus has been transmitted from an
infected male to a female sexual partner. The CDC advises that the virus
can be spread during sex regardless of whether the man has symptoms or
not. CDC guidelines recommend that if a male is infected, non-pregnant
couples should use a condom every time they have sex to prevent possible
infection or abstain from sex for at least six months. For pregnant
couples, this recommendation also applies but for the duration of the
pregnancy.

The VivaGel® condom, marketed in Australia as the Dual
Protect™ condom by Ansell, contains the antiviral VivaGel®
active. The physical barrier of the condom provides primary protection
against sexually transmitted infections (STIs), while VivaGel®
is included in the condom lubricant as an antiviral agent that has been
proven, in laboratory studies only, to inactivate HIV, HSV and HPV,
which are viruses that cause STIs. In view of the potent antiviral
activity identified for the VivaGel® active against Zika
virus, Starpharma is now investigating the inclusion of Zika in the list
of viruses inactivated for the VivaGel® condom.

Given the outbreak in Brazil, the host nation for the 2016 Olympic
Games, health authorities, including the CDC, are issuing guidelines for
their athletes, spectators and officials traveling to the Olympics in
Rio. It has been reported that Olympic teams, including the Australian
and US teams, are carefully monitoring the situation and considering all
available preventive measures for their athletes.

Starpharma CEO, Dr Jackie Fairley, commented, “There is currently no
vaccine or therapy available for Zika virus. Given sexually transmitted
infection is of increasing importance, the potent activity of the VivaGel®
active against Zika virus could prove very important from a public
health standpoint and a significant commercial opportunity.”

Scientists continue to study the full range of other potential health
problems that Zika virus infection during pregnancy may cause. While
Zika virus disease in adults is rarely fatal, there continue to be
reports that the neurological effects of Zika, including cases of
Guillain-Barré syndrome, could be even worse than first thought.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), located in
Melbourne Australia, is an ASX 300 company and is a world leader in the
development of dendrimer products for pharmaceutical, life science and
other applications. For more information please visit: www.starpharma.com

Copyright © 2016 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/SPHRY/news?id=131112

Endonovo Therapeutics, Inc. (ENDV: OTCQB) | Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York

Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York

May 05, 2016

OTC Disclosure News Service

– Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York

LOS ANGELES, CA–(Marketwired – May 5, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), an innovative biotechnology company developing a bioelectronic approach to regenerative medicine, announced today that Endonovo Chairman CEO, Alan Collier, will present a company overview at the 2016 Marcum Microcap Conference on June 2, 2016. The event will be held at the Grand Hyatt New York on Park Avenue at Grand Central.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo’s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo’s Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

Investors: Sign Up for Email Alerts on Endonovo

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

Copyright © 2016 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/ENDV/news?id=131088

CCOM Group, Inc. (CCOM: OTC Pink Limited) | CCOM Group, Inc. Reports 2016 First Quarter Results

CCOM Group, Inc. Reports 2016 First Quarter Results

May 05, 2016

OTC Disclosure News Service

CCOM Group, Inc. (“CCOM”) (OTC Pink: “CCOM,” “CCOMP”), announced its
financial results for the quarter ended March 31, 2016.

Results for the quarter ended March 31, 2016 compared to results for the
same period in 2015:

  • Sales increased 14.9% to $17,878,764 from $15,556,262
  • Gross profit increased 7.1% to $4,940,991 from $4,611,326
  • Selling, general and administrative expenses increased 5.0% to
    $5,461,201 from $5,201,329
  • Operating loss decreased 11.8% to $520,210 from $590,003
  • Net loss decreased 8.7% to $617,777 from $676,559
  • Net loss per share on a fully diluted basis remained the same at
    $(0.07) per share

About CCOM Group, Inc.

CCOM Group, Inc. (“CCOM”) distributes heating, ventilating and air
conditioning equipment (HVAC), parts and accessories, whole-house
generators, climate control systems, and plumbing and electrical
fixtures and supplies, primarily in New Jersey, New York, Massachusetts
and portions of eastern Pennsylvania, Connecticut and Vermont through
its subsidiaries: Universal Supply Group, Inc., www.usginc.com,
The RAL Supply Group, Inc., www.ralsupply.com,
American/Universal Supply Division, www.ausupplyinc.com,
and SA Supply, Inc., www.sasupplyinc.com.
CCOM is headquartered in New Jersey, and, with its affiliates, operates
out of 17 locations in its geographic trading area. For more information
on CCOM’s operations, products and/or services, please visit www.ccomgrp.com.

(Financial Highlights Follow)

 

 

 

 

 

 

 

CCOM GROUP, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

 

March 31,

December 31,

2016

2015

(Unaudited)

 

Assets

Current assets:

Cash

$

421,805

$

577,303

Accounts receivable, net of allowance for doubtful accounts
of
$1,093,282 and $1,086,213, respectively

9,644,732

10,043,006

Inventory

18,521,018

13,545,954

Prepaid expenses and other current assets

920,511

777,757

Deferred tax asset

 

170,000

 

 

170,000

 

Total current assets

29,678,066

25,114,020

Property and equipment

832,545

889,866

Goodwill

1,416,929

1,416,929

Other assets – noncurrent

4,363

6,981

Deferred tax asset – noncurrent

 

2,296,500

 

 

2,296,500

 

$

34,228,403

 

$

29,724,296

 

Liabilities and Stockholders’ Equity

Current liabilities:

Borrowings under credit facility – revolving credit

$

13,334,755

$

12,716,527

Notes payable – current portion; includes related party notes
of
$2,166,050 and $162,773, respectively

2,323,100

325,895

Trade payables

6,243,877

3,833,579

Accrued liabilities

1,550,443

1,373,073

Income taxes payable

 

420

 

 

420

 

Total current liabilities

23,452,595

18,249,494

Convertible notes payable, excluding current portion-related party

200,000

200,000

Notes payable, excluding current portion; includes related party
notes
of $929,399 and $972,161, respectively

1,079,500

1,160,717

Deferred tax liability – noncurrent

 

567,000

 

 

567,000

 

Total liabilities

 

25,299,095

 

 

20,177,211

 

 

Commitments and contingencies

Stockholders’ equity:

Redeemable convertible preferred stock, $.05 par value,
2,500,000
shares authorized, 284,612 shares issued and
outstanding,
liquidation preference of $1,423,060

14,231

14,231

Common stock, $.05 par value, 20,000,000 shares authorized,
9,154,928
shares issued and outstanding

457,746

457,746

Additional paid-in capital

12,596,853

12,596,853

Accumulated deficit

 

(4,139,522

)

 

(3,521,745

)

Total stockholders’ equity

 

8,929,308

 

 

9,547,085

 

$

34,228,403

 

$

29,724,296

 

 

 

 

 

 

 

 

 

 

CCOM GROUP, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

 

For the Three Months Ended

March 31,

2016

2015

Sales

$

17,878,764

$

15,556,262

Cost of sales

 

12,937,773

 

 

10,944,936

 

Gross profit

4,940,991

4,611,326

 

Selling, general and administrative expenses, net

 

5,461,201

 

 

5,201,329

 

Operating loss

(520,210

)

(590,003

)

 

Other income

43,517

44,872

Interest expense, net; includes related party interest
of
$29,666 and $29,598, respectively

 

(141,084

)

 

(131,428

)

Net loss

$

 

(617,777

)

$

 

(676,559

)

 

 

Loss per common share:

Basic and diluted

$

(0.07

)

$

(0.07

)

 

Weighted average shares
outstanding:

Basic and diluted

 

9,154,928

 

 

9,154,953

 

 

 

 

 

 

 

 

 

 

 

 

CCOM GROUP, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

For The Three Months Ended

March 31,

2016

2015

Cash flows from operating activities:

Net loss

$

(617,777

)

$

(676,559

)

Adjustments to reconcile net loss to net cash
used in
operating activities:

Provision for doubtful accounts

31,405

54,868

Depreciation

87,991

76,946

Net gain on sale of fixed assets

(957

)

Changes in operating assets and liabilities

Accounts receivable

366,869

867,939

Inventory

(4,975,064

)

(2,648,467

)

Prepaid expenses and other current assets

(142,754

)

(105,962

)

Other assets – noncurrent

2,618

11,443

Trade payables

2,410,298

665,740

Accrued liabilities

177,370

191,557

Income taxes payable

 

(16,087

)

Net cash used in operating activities

(2,660,001

)

(1,578,582

)

 

Cash flows from investing activities:

Additions to property and equipment

(37,760

)

(4,941

)

Proceeds from disposal of property and equipment

8,047

 

 

Net cash used in investing activities

(29,713

)

(4,941

)

 

Cash flows from financing activities:

Repayments of notes payable: includes related party
repayments
of $789,485 and $786,459 respectively

(834,012

)

(822,554

)

Issuance of notes payable, related party

2,750,000

1,500,000

Repayments under credit facility – revolving credit, net

618,228

 

995,914

 

Net cash provided by financing activities

2,534,216

 

1,673,360

 

(Decrease) increase in cash

(155,498

)

89,837

Cash – beginning of period

577,303

 

238,696

 

Cash – end of period

$

421,805

 

$

328,533

 

 

Copyright © 2016 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/CCOM/news?id=131066

Bunk Beds